Transgene : Composition of the Board of Directors and Statutory Auditors

STRASBOURG, France–(BUSINESS WIRE)– class= »bwalignl »>
Regulatory News:

Transgene (Euronext Paris:TNG), a company focused on designing and
developing targeted immunotherapies for the treatment of cancer and
infectious diseases, announced the new composition of its board of
directors and the appointment of new statutory auditors following
yesterday’s annual shareholders’ meeting (AGM).

The AGM appointed Mr Antoine Béret¹ as an independent
director, to replace Mr Arnaud Fayet who did not seek a renewal of his
term.

“We warmly thank Arnaud Fayet who has accompanied us since 2000,
including as chairman of our audit committee. His strong professional
skills, his availability, his open mindset and his human qualities have
been precious to us over the course of these years,” said Philippe
Archinard, Chairman and CEO of Transgene. He added: “We are pleased to
welcome Antoine Béret. He brings us decades of experience in creating
and directing businesses in our industry and we look forward to
benefiting from them over the next steps of our development.”

In addition, the AGM has:

• renewed the mandates of Mr Jean-Luc Bélingard and three independent
  directors: Prof. Laurence Zitvogel, MD, Jean-Pierre Bizzari, MD, and
  Mr Jean-François Labbé. The board of directors is composed of 10
  members, including six independent directors;
• renewed the mandates of Ernst et Young & Autres and Auditex as primary
  and substitute statutory auditors respectively and appointed two new
  statutory auditors: Grant Thornton (primary) and IGEC company
  (substitute); and
• voted the other resolutions submitted, in accordance with the
  recommendations of the Board of Directors.

About Transgene

Transgene S.A. (Euronext: TNG), part of Institut Mérieux, is a publicly
traded French biopharmaceutical company focused on designing and
developing targeted immunotherapies for the treatment of cancer and
infectious diseases. Transgene’s programs utilize viral vector
technology with the goal of indirectly or directly killing infected or
cancerous cells. The Company’s two lead clinical-stage programs are:
TG4010 for non-small cell lung cancer and Pexa-Vec for liver cancer. The
Company has several other programs in clinical and pre-clinical
development. Transgene is based in Strasbourg, France, and has
additional operations in Lyon, as well as satellite offices in China and
the U.S. Additional information about Transgene is available at www.transgene.fr.

¹ Antoine Béret (71 years old, French citizen), has been
Chief Executive Officer (CEO) of Genoscience Pharma SAS since 2012 and
Chairman of Axenis. He graduated from Ecole Nationale des Ponts et
Chaussées and Ecole Polytechnique. M. Béret co-founded several companies
specializing in biomedicine, including Trophos where he served as CEO
until 2008 and Immunotech that he directed until 1996 when Immunotech
was acquired by Coulter Inc. He started his career as a civil
engineer in both public and private sectors, then has been project
manager in charge of funding industrial companies at Crédit National and
directed and invested as a ‘business angel’ TxCell in 2001-2002.

View source version on businesswire.com: http://www.businesswire.com/news/home/20160525006147/en/